BioCentury | Feb 8, 2016
Company News

Annapurna Therapeutics, Avalanche Biotechnologies deal

...vector delivering the human frataxin ( FXN ; FRDA) gene to treat Friedreich’s ataxia; and ANN-004...
...an AAV vector to treat severe allergies. Annapurna has exclusive rights to ANN-001, ANN-002 and ANN-004...
Items per page:
1 - 1 of 1